Bichet D G, Turner M, Morin D
Department of Medecine, Université de Montréal and Research Center, Hôpital du Sacré-Coeur de Montréal, Québec, Canada.
Proc Assoc Am Physicians. 1998 Sep-Oct;110(5):387-94.
In congenital nephrogenic diabetes insipidus, the renal collecting ducts are resistant to the antidiuretic action of arginine vasopressin or to its antidiuretic analog 1-deamino[8-D-arginine] vasopressin (dDAVP). This is a rare, but now well described entity secondary to either mutations in the AVPR2 gene that codes for the vasopressin antidiuretic (V2) receptor or to mutations in the AQP2 gene that codes for the vasopressin-dependent water channel. A majority (> 90%) of congenital nephrogenic diabetes insipidus patients have AVPR2 mutations: Of 115 families with congenital nephrogenic diabetes insipidus, 105 families had AVPR2 mutations, and 10 had AQP2 mutations. When studied in vitro, most AVPR2 mutations lead to receptors that are trapped intracellularly and are unable to reach the plasma membrane. A minority of the mutant receptors reach the cell surface but are unable to bind vasopressin or to trigger an intracellular adenosine 3:5-cyclic phosphate signal properly. Most of the reported mutations are secondary to a complete loss of function of the receptor, and only a few mutations have been associated with a mild phenotype. These advances provide diagnostic tools for physicians caring for these patients because, when the disease causing mutation has been identified, carrier and perinatal testing could be done by mutation analysis.
在先天性肾性尿崩症中,肾集合管对精氨酸加压素的抗利尿作用或其抗利尿类似物1-去氨基[8-D-精氨酸]加压素(dDAVP)具有抗性。这是一种罕见但现已得到充分描述的病症,继发于编码加压素抗利尿(V2)受体的AVPR2基因突变或编码加压素依赖性水通道的AQP2基因突变。大多数(>90%)先天性肾性尿崩症患者存在AVPR2突变:在115个先天性肾性尿崩症家庭中,105个家庭有AVPR2突变,10个家庭有AQP2突变。在体外研究时,大多数AVPR2突变导致受体被困在细胞内,无法到达质膜。少数突变受体到达细胞表面,但无法结合加压素或正常触发细胞内3:5-环磷酸腺苷信号。大多数报道的突变继发于受体功能的完全丧失,只有少数突变与轻度表型相关。这些进展为治疗这些患者的医生提供了诊断工具,因为当确定致病突变后,可通过突变分析进行携带者和围产期检测。